Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures: An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy Measures: An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced Non-small Cell Lung Cancer

Published:2008-01 Issue:1 Volume:3 Page:30-36
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

de Marinis Filippo,Pereira Jose Rodrigues,Fossella Frank,Perry Michael C.,Reck Martin,Salzberg Marc,Jassem Jacek,Peterson Patrick,Liepa Astra M.,Moore Patti,Gralla Richard J.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. Second-line treatment for advanced non-small cell lung cancer: a systematic review;Barlesi;Lung Cancer,2006

2. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline;Noble;J Thoracic Oncol,2006

3. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;Hanna;J Clin Oncol,2004

4. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS);Hollen;Eur J Cancer,1993

5. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale;Hollen;Cancer,1994

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review;Lung Cancer;2024-01

2. Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study;Lung Cancer;2020-12

3. The Relevance of Docetaxel-related Febrile Neutropenia to Patient-reported Symptoms and the Quality of Life in Japanese, East Asian (Korean, Taiwanese), and Non-East Asian Patients Based on Post-hoc Analyses of Two Randomized Clinical Trials of Docetaxel with and Without Anti-angiogenic Agent in Advanced Non-small Cell Lung Cancer After Progression on Platinum-based Chemotherapy;Haigan;2019-12-20

4. US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017;The Lancet Oncology;2019-10